DrugPatentWatch Database Preview
ARNUITY ELLIPTA Drug Profile
When do Arnuity Ellipta patents expire, and what generic alternatives are available?
Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are eight patents protecting this drug.
This drug has two hundred and seventy patent family members in forty-one countries.
The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for ARNUITY ELLIPTA
| International Patents: | 270 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 16 |
| Clinical Trials: | 2 |
| Patent Applications: | 529 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ARNUITY ELLIPTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARNUITY ELLIPTA |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for ARNUITY ELLIPTA |
| DailyMed Link: | ARNUITY ELLIPTA at DailyMed |
Pharmacology for ARNUITY ELLIPTA
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for ARNUITY ELLIPTA
| (6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate |
| (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate |
| 397864-44-7 |
| 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| 779352-12-4 |
| 911210-90-7 |
| Alisade |
| Allermist |
| Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)- |
| Avamys |
| Avamys pound>> Veramyst pound>> Allermist |
| BCP18136 |
| BDBM50354851 |
| CHEBI:74899 |
| CHEMBL1676 |
| D06315 |
| DB08906 |
| DTXSID60228586 |
| Flonase Sensimist |
| Flonase Sensimist Allergy Relief |
| Fluticasone fuorate |
| Fluticasone furancarboxylate |
| Fluticasone furoate |
| Fluticasone furoate (JAN/USAN/INN) |
| Fluticasone furoate [USAN:INN] |
| fluticasonum furoas |
| FT-0668768 |
| Furamist |
| furoate de fluticasone |
| furoato de fluticasona |
| GSK 685 698 |
| GSK 685698 |
| GW 685698 |
| GW 685698X |
| GW-685698 |
| GW-685698X |
| GW6 |
| gw685698 |
| GW685698X |
| JS86977WNV |
| SCHEMBL140504 |
| UNII-JS86977WNV |
| Veramyst |
| Veramyst (TN) |
| ZINC3992105 |
US Patents and Regulatory Information for ARNUITY ELLIPTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-003 | May 17, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for ARNUITY ELLIPTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for ARNUITY ELLIPTA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007012871 | ➤ Try a Free Trial |
| Germany | 122008000029 | ➤ Try a Free Trial |
| Japan | 2005523268 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for ARNUITY ELLIPTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1305329 | 12/2008 | Austria | ➤ Try a Free Trial | PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/07/434/001 - EU/1/07/434/003 20080111 |
| 1305329 | SPC/GB08/026 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111 |
| 1305329 | CA 2008 00022 | Denmark | ➤ Try a Free Trial | |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
